As U.S. consumers are asked to shoulder more prescription drug costs, drugmakers say prices for brand-name medicines will keep rising, mainly because use of their products reduces other healthcare costs
Are those AstraZeneca investors jumping ship? AstraZeneca’s new boss said sales and profits would both fall sharply in 2013 as the drugmaker struggles to turn itself around by investing more in-house and on potential acquisitions.
Drugs refilled without patient’s approval. According to the Los Angeles Times, at least some pharmacists at CVS, the nation’s second-largest drugstore chain, have refilled prescriptions and submitted claims to insurers without patients’ approval.
For more than a decade generic drug makers and big-name pharmaceutical companies have been winning court rulings that allowed them to legally pay a competitor to keep its product off the market for years. Until this month.
A Health Affairs article by Ubel et al. reveals that while oncologists are sensitive to price in the abstract, they tend to yield their cost-effectiveness notions when considering treatment for individual patients.